Biognosys has launched its proprietary P2 Plasma Enrichment method, which is a single-well, single particle-type enrichment designed to enhance the throughput in plasma proteomics research in human and animal-model clinical studies. The technical and performance details are planned to be presented at the American Society of Mass Spectrometry (ASMS) Annual Conference which will be held on June 3, 2024.

The product is designed to increase the depth and throughput of plasma proteomics by stabilizing the labile protein corona formed around plasma particles. According to the company, in a previously published five-cancer plasma sample set, the novel method has achieved a proteome coverage of 7,000 proteins, demonstrating high enrichment of low-abundant proteins and high throughput on Bruker timsTOF HT mass spectrometers. 

Switzerland-based Biognosys is a biotechnology company specializing in next-generation proteomics. The company’s platform-based product offerings include the True Discovery integrated proteomics drug development solution powered by its patented Hyper Reaction Monitoring (HRM) mass spectrometry, True Target, which identifies targets and de-risks the drug development process, as well as TrueSignature, which provides customizable proteomics panels for pharmacodynamic readouts and precise clinical biomarker monitoring.